CL2024000207A1 - Proteínas de unión a antígeno que se unen específicamente a ct45 - Google Patents
Proteínas de unión a antígeno que se unen específicamente a ct45Info
- Publication number
- CL2024000207A1 CL2024000207A1 CL2024000207A CL2024000207A CL2024000207A1 CL 2024000207 A1 CL2024000207 A1 CL 2024000207A1 CL 2024000207 A CL2024000207 A CL 2024000207A CL 2024000207 A CL2024000207 A CL 2024000207A CL 2024000207 A1 CL2024000207 A1 CL 2024000207A1
- Authority
- CL
- Chile
- Prior art keywords
- antigen binding
- binding proteins
- binding protein
- polypeptide
- protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163203582P | 2021-07-27 | 2021-07-27 | |
| EP21188018 | 2021-07-27 | ||
| US202263335399P | 2022-04-27 | 2022-04-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2024000207A1 true CL2024000207A1 (es) | 2024-06-14 |
Family
ID=82939905
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2024000207A CL2024000207A1 (es) | 2021-07-27 | 2024-01-24 | Proteínas de unión a antígeno que se unen específicamente a ct45 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US12209137B2 (https=) |
| EP (1) | EP4377330A1 (https=) |
| JP (1) | JP2024529467A (https=) |
| KR (1) | KR20240038028A (https=) |
| AU (1) | AU2022318257A1 (https=) |
| CA (1) | CA3226437A1 (https=) |
| CL (1) | CL2024000207A1 (https=) |
| CO (1) | CO2024000677A2 (https=) |
| IL (1) | IL310374A (https=) |
| MX (1) | MX2024001179A (https=) |
| PE (1) | PE20240779A1 (https=) |
| TW (1) | TW202321277A (https=) |
| WO (1) | WO2023006828A1 (https=) |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
| US4861719A (en) | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
| GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5278056A (en) | 1988-02-05 | 1994-01-11 | The Trustees Of Columbia University In The City Of New York | Retroviral packaging cell lines and process of using same |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5670488A (en) | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
| DE69434860T2 (de) | 1993-02-22 | 2007-03-15 | The Rockefeller University | Herstellung von helfer-freien retroviren mit hohem titer mittels transienter transfektion |
| FR2712812B1 (fr) | 1993-11-23 | 1996-02-09 | Centre Nat Rech Scient | Composition pour la production de produits thérapeutiques in vivo. |
| IL116816A (en) | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
| ES2233974T3 (es) | 1995-09-11 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | Anticuerpo contra la cadena alfa del receptor de la interleucina 5 humana. |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| CA2243235C (en) | 1996-01-17 | 2010-08-10 | Imperial College Innovations Limited | Immunotherapy using cytotoxic t lymphocytes (ctl) |
| MXPA02005559A (es) | 1999-12-06 | 2004-09-10 | Univ Illinois | Proteinas de tcr de alta afinidad y metodos. |
| DE10225139A1 (de) | 2002-05-29 | 2004-02-26 | Immatics Biotechnologies Gmbh | Verfahren zur Identifizierung von immunreaktiven Peptiden |
| US7751825B2 (en) | 2002-06-27 | 2010-07-06 | Qualcomm Incorporated | Controlling geographic location information of devices operating in wireless communication systems |
| GB0308731D0 (en) | 2003-04-15 | 2003-05-21 | Anticancer Therapeutic Inv Sa | Method of radiotherapy |
| WO2005076009A2 (en) | 2004-01-28 | 2005-08-18 | Immatics Biotechnologies Gmbh | Method for identifying and quantifying of tumour-associated peptides |
| US20110177079A1 (en) | 2004-09-08 | 2011-07-21 | Ludwig Institute For Cancer Research | Cancer-testis antigens |
| US9840695B2 (en) | 2009-04-28 | 2017-12-12 | Agriculture Victoria Services Pty Ltd | Plant technology |
| EP2486049A1 (en) | 2009-10-06 | 2012-08-15 | The Board Of Trustees Of The UniversityOf Illinois | Human single-chain t cell receptors |
| GB201006360D0 (en) | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
| KR102499753B1 (ko) | 2012-07-27 | 2023-02-16 | 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 | Ｔ 세포 수용체 조작 |
| TR201905447T4 (tr) * | 2012-12-14 | 2019-05-21 | Biontech Rna Pharmaceuticals Gmbh | Yeni mhc bağımsız tümörle ilişkili antijenler. |
| GB201423361D0 (en) | 2014-12-30 | 2015-02-11 | Immatics Biotechnologies Gmbh | Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides |
| US11261223B2 (en) | 2016-05-11 | 2022-03-01 | The University Of Chicago | Methods of treating cancers with CT45 targeted therapies |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| LT3428194T (lt) | 2017-07-14 | 2021-12-10 | Immatics Biotechnologies Gmbh | Pagerinta dvejopo savitumo polipeptido molekulė |
| US20220175899A1 (en) | 2019-04-11 | 2022-06-09 | The Board Of Trustees Of The Leland Stanford Junior University | Cytotoxic t lymphocytes specific for mutated forms of epidermal growth factor receptor for use in treating cancer |
-
2022
- 2022-07-27 PE PE2024000153A patent/PE20240779A1/es unknown
- 2022-07-27 TW TW111128129A patent/TW202321277A/zh unknown
- 2022-07-27 JP JP2024505122A patent/JP2024529467A/ja active Pending
- 2022-07-27 IL IL310374A patent/IL310374A/en unknown
- 2022-07-27 KR KR1020247005786A patent/KR20240038028A/ko active Pending
- 2022-07-27 MX MX2024001179A patent/MX2024001179A/es unknown
- 2022-07-27 EP EP22755209.8A patent/EP4377330A1/en active Pending
- 2022-07-27 WO PCT/EP2022/071104 patent/WO2023006828A1/en not_active Ceased
- 2022-07-27 AU AU2022318257A patent/AU2022318257A1/en active Pending
- 2022-07-27 US US17/874,711 patent/US12209137B2/en active Active
- 2022-07-27 CA CA3226437A patent/CA3226437A1/en active Pending
-
2024
- 2024-01-24 CL CL2024000207A patent/CL2024000207A1/es unknown
- 2024-01-25 CO CONC2024/0000677A patent/CO2024000677A2/es unknown
- 2024-12-20 US US18/989,486 patent/US20250122302A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022318257A1 (en) | 2024-02-08 |
| TW202321277A (zh) | 2023-06-01 |
| KR20240038028A (ko) | 2024-03-22 |
| CO2024000677A2 (es) | 2024-05-10 |
| PE20240779A1 (es) | 2024-04-17 |
| US20230057987A1 (en) | 2023-02-23 |
| CA3226437A1 (en) | 2023-02-02 |
| MX2024001179A (es) | 2024-02-27 |
| JP2024529467A (ja) | 2024-08-06 |
| EP4377330A1 (en) | 2024-06-05 |
| US12209137B2 (en) | 2025-01-28 |
| WO2023006828A1 (en) | 2023-02-02 |
| IL310374A (en) | 2024-03-01 |
| US20250122302A1 (en) | 2025-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR120585A1 (es) | Proteínas de unión a antígenos que se unen específicamente a mage-a | |
| AR121588A2 (es) | Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer | |
| CO2023014734A2 (es) | Polipéptidos de unión a antígeno bma031 mejorados | |
| CO2023014722A2 (es) | Proteínas de unión a antígenos que se unen específicamente a prame | |
| ATE468127T1 (de) | Ii-key/antigene epitop-hybrid-peptid-vakzine | |
| CN114174329A (zh) | 肽-mhc复合物 | |
| BR112023025884A2 (pt) | Proteína de fusão de domínio de ligante de anticorpo de nkg2d | |
| ES3009108T3 (en) | Hla-b57 open conformers | |
| CL2009001284A1 (es) | Anticuerpos o fragmentos de union a antigeno del mismo que se unen a il-21r; composicion farmaceutica que lo comprende; acidos nucleicos codificantes; vectores de expresion y celulas huesped aisladas; kit de diagnostico que comprende a dichos anticuerpos | |
| Pecorari et al. | Folding, heterodimeric association and specific peptide recognition of a murine αβ T-cell receptor expressed in Escherichia coli | |
| CL2024000207A1 (es) | Proteínas de unión a antígeno que se unen específicamente a ct45 | |
| PE20240589A1 (es) | ANTICUERPOS CD1a Y SU USO | |
| AR133400A1 (es) | Proteínas de unión a antígeno contra mageb2 | |
| AR126579A1 (es) | Proteínas de unión a antígeno que se unen específicamente a ct45 | |
| ATE509025T1 (de) | ßMIT MHC-KLASSE-I-PEPTIDEPITOPEN KOVALENT VERKN PFTES MEMBRANVERANKERTES BETA2-MIKROGLOBULINß | |
| AR127176A1 (es) | Polipéptidos de unión a antígeno, complejos de polipéptidos de unión a antígeno y métodos de uso de los mismos | |
| PE20240369A1 (es) | Anticuerpos anti-tigit, anticuerpos anti-cd96 y metodos de uso de estos | |
| Nemoto et al. | A disulfide bridge mediated by cysteine 574 is formed in the dimer of the 70-kDa heat shock protein | |
| ES2664725T3 (es) | Métodos y materiales para generar células T CD8+ con la capacidad para reconocer células cancerígenas que expresen un polipéptido HER2/neu | |
| CN110511273A (zh) | 一种高效细胞穿膜多肽的制备方法及其应用 | |
| CN101103108A (zh) | Hla-结合肽，和编码所述hla-结合肽的dna片段以及重组载体 | |
| JP2025514872A5 (https=) | ||
| CN111116744A (zh) | 哺乳动物eEF1Bα蛋白磷酸化Ser106位点的特异性抗体的制备方法及其应用 | |
| JP2015514726A5 (https=) | ||
| AR130387A1 (es) | Receptores de linfocitos t recombinantes |